Severe gastrointestinal side effects from either medication can lead to reduced fluid intake and increased fluid loss, potentially affecting kidney function
Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations
Weight loss percentages are typically lower for people starting with lower BMI: expect 515% body weight reduction over 612 months, compared to 1522% in higher BMI clinical trials
Rodriguez J, Strong AT, Haskins IN, Landreneau JP, Allemang MT, El-Hayek K, et al
It may also support intestinal mobility in the removal of pathogenic bacteria, producing improvement of microflora balance and a well-maintained digestive system through colonisation of beneficial microbial populations (Bellikci-Koyu et al., 2019
The 2023 New England Journal of Medicine publication described a randomized, double-blind, placebo-controlled Phase 2 trial in adults with obesity or overweight with at least one related condition